Topic: heart disease

Joe Jimenez

Novartis' Entresto gets more love in EU than U.S.

Novartis is seeing much faster uptake of heart failure drug Entresto in Europe as payer pushback in the U.S. on Entresto and some other new generation heart drugs are dulling sales in what is usually the best market for new meds.
AbbVie HQ

FDA pulls approvals on AbbVie's ex-blockbuster heart meds

Years after questions first arose about their usefulness, the FDA has pulled approvals on four AbbVie heart meds. The former blockbuster meds had already fallen out of favor, and generics started eroding sales in 2013. The company has already pulled two of them, Advicor and Simcor, off the market.